Policy
Drug pricing watchdog ICER offers ways to increase obesity drug access
ICER, Obesity, Access, Wegovy, Policy, drug price
FDAs policy, communications staff likely to be among agencys 3,500 staff cuts
Policy, Communication, Staff, United States Food and Drug Administration, CHARGE Syndrome
Trump’s Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact
Trump, pharmaceutical tariffs, trade policy, drug prices, manufacturing, supply chain
CDC Vaccine Advisory Committee Meeting Postponed Following RFK Jr.’s Confirmation as HHS Secretary
ACIP, CDC, vaccine recommendations, Robert F. Kennedy Jr., HHS, postponement, public health, immunization policy
Trump Imposes New Tariffs on Canada, Mexico, and China; Medical Industry Seeks Exemptions
Trump tariffs, Canada, Mexico, China, medical technology exemptions, trade policy, national security, fentanyl crisis, illegal immigration
Trump 2.0: RFK Confirmation Hearings and Ongoing Clinical Trials Amidst Administrative Changes
Trump 2.0, RFK Confirmation Hearings, Clinical Trials, NIH Grant Reviews, US-India Partnership, Second Term Policies
Trump’s Re-Election: A Mixed Bag for Biopharma with M&A Upsides and Vaccine Concerns
Trump Administration, Biopharma, Mergers and Acquisitions, Vaccine Policy, Robert F. Kennedy Jr., FDA Independence, Inflation Reduction Act
Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals
Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty
Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration
RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy
Federal Agency Rejects J&J’s 340B Rebate Model, Vows to Take Action
340B Program, Johnson & Johnson, Rebate Model, Federal Agency Opposition, Healthcare Policy